French biopharmaceutical company Valneva is undergoing a significant restructuring, including a reduction of its global workforce by up to 15%. This move follows a substantial decline in first-quarter revenues and aims to reduce operating costs.
What happened
Valneva launched a restructuring plan involving global headcount reductions and operational consolidation. This includes closing its R&D center in Nantes, France, eliminating 30 out of 39 positions there. The plan seeks to cut overall operating costs by 25% to 35% compared to 2025 levels, primarily through reduced research and development spending.
How many employees affected
Valneva plans to reduce its global workforce by between 10% and 15%. The company began 2026 with 674 employees, meaning up to 101 employees could be affected. Specifically, 30 positions are being eliminated with the Nantes R&D center closure.
Why layoffs happened
The layoffs respond to a challenging financial picture, with first-quarter 2026 revenues falling nearly 40% to 30.9 million euros from 49.2 million euros year-over-year. Factors include a strategic shift from distributing third-party vaccines, changes in military delivery schedules, and an early slowdown in travel vaccine demand due to geopolitical tensions.
Company background
Valneva is a French biopharmaceutical company specializing in vaccines, with operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. It is notably co-developing a Lyme disease vaccine with Pfizer.
Industry impact
While the sources do not detail broader industry impact, Valneva's situation highlights financial pressures and strategic shifts within the biopharmaceutical sector, particularly for vaccine developers.
What's next
Despite current turbulence, Valneva's primary focus remains its Lyme disease vaccine, co-developed with Pfizer, which has shown promising efficacy in Phase 3 trials and is moving towards regulatory submissions. The company is also progressing with its chikungunya vaccine and anticipates a decision soon regarding its Shigella vaccine candidate.